EcoR1 Capital’s Praxis Precision Medicines PRAX Stock Holding History

EcoR1 Capital’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-105,688	Closed	-$3.77M	–	66
2022 Q4	$3.77M	Buy	105,688 +5,933	+6%	+$185K	0.11%	50
2022 Q3	$3.4M	Buy	99,755 +85,748	+612%	+$4.27M	0.1%	55
2022 Q2	$515K	Buy	+14,007	New	+$1.49M	0.02%	74

Other funds holding PRAX

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

EcoR1 Capital's PRAX Position: Q1 2023 in Review

EcoR1 Capital sold out of Praxis Precision Medicines (PRAX) in Q1 2023, closing a stake of 105,688 shares — an estimated $3.77M sold.

EcoR1 Capital first reported a position in PRAX in Q2 2022 and held it in 3 quarters. The position peaked at $3.77M in Q4 2022. 86 funds tracked by Wall St. Rank hold PRAX as of Q1 2023.

EcoR1 Capital reported no remaining Praxis Precision Medicines position as of Q1 2023 after selling out during the quarter.
EcoR1 Capital sold 105,688 Praxis Precision Medicines shares in Q1 2023, an estimated $3.77M.
EcoR1 Capital first reported a position in Praxis Precision Medicines in Q2 2022 and held it in 3 quarters.
EcoR1 Capital's Praxis Precision Medicines position peaked at $3.77M in Q4 2022.
86 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2023.

Based on EcoR1 Capital's 13F filing for Q1 2023, filed 15 May 2023.